Efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients: a single-centre experience.
Combined modality therapy
Hodgkin lymphoma
Late complications
Non-Hodgkin's lymphoma
Radiotherapy
Survival
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
09
11
2022
accepted:
28
02
2023
medline:
24
4
2023
pubmed:
16
3
2023
entrez:
15
3
2023
Statut:
ppublish
Résumé
Data on efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients are scarce. We therefore performed this retrospective study to analyse our experience with radiotherapy exclusively to infradiaphragmal fields. we retrospectively evaluated 101 patients treated between 2003 and 2014. Median dose was 36 Gy, range 4 to 54 Gy. Medium dose per fraction was 2 Gy, range 1.5 to 7 Gy. After a median follow-up of 66 months (range 1-211 months), we observed lymphoma recurrence in 38 patients (38%), five in the RT field and 33 out-of-field. Recurrences were significantly more frequent in the salvage group (17 out-of-field and 4 in-field in 31 patients) than in adjuvant group (16 out-of-field and 1 in-field in 70 patients; p < 0.001). The 2-, 5- and 10-year event-free survival (EFS) rates were 62%, 56% and 54%. The 2-, 5- and 10-year overall survival (OS) rates for the entire group of patients are 73%, 60% and 54%, respectively. Acute side effects occurred in 43 (43%) patients, most frequent gastrointestinal in 26 (26%) patients. Late side effects occurred in 12 (12%) of all patients, 6 of 23 (26%) followed up for more than 10 years. Six patients developed secondary cancers, four gastrointestinal disturbances, two diabetes mellitus and three renal failure. Radiotherapy is an effective and safe treatment option for patients with infradiaphragmatic lymphoma providing excellent local disease control with minimal late toxicity. Infradiaphragmatic lymphoma localization should not be regarded as a contraindication for use of radiotherapy. However, patients should be monitored for a secondary malignancy.
Identifiants
pubmed: 36920724
doi: 10.1007/s11547-023-01615-8
pii: 10.1007/s11547-023-01615-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
492-500Informations de copyright
© 2023. Italian Society of Medical Radiology.
Références
Joiner M, Kogel A (2009) Basic clinical radiobiology, 4th edn. CRC Press, Abingdon, Oxon
doi: 10.1201/b15450
Shi Z, Das S, Okwan-Doudu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil JL, Khan KM (2013) Patterns of failure in advanced stage diffuse large B cell lymphoma after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys 86:569–577
doi: 10.1016/j.ijrobp.2013.02.007
pubmed: 23540349
Held G, Murawski N, Ziepert M, Fleckenstein J, Pochel V, Zwick C et al (2014) Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 32(11):1112–1118. https://doi.org/10.1200/JCO.2013.51.4505
doi: 10.1200/JCO.2013.51.4505
pubmed: 24493716
Longo DL (1989) Combined modality therapy for localized aggressive lymphoma: enough or too much? J Clin Oncol 7(9):1179–1181. https://doi.org/10.1200/JCO.1989.7.9.1179
doi: 10.1200/JCO.1989.7.9.1179
pubmed: 2769325
Specht L (2016) Does radiation have a role in advanced stage hodgkin’s or Non-Hodgkin lymphoma? Curr Treat Options Oncol 17(1):4. https://doi.org/10.1007/s11864-015-0377-x
doi: 10.1007/s11864-015-0377-x
pubmed: 26739151
Milgrom SA, Bakst RL, Campbell BA (2021) Clinical outcomes confirm conjecture: modern radiation therapy reduces the risk of late toxicity in survivors of Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 111(4):841–850. https://doi.org/10.1016/j.ijrobp.2021.06.030
doi: 10.1016/j.ijrobp.2021.06.030
pubmed: 34655558
Conway JL, Connors JM, Tyldesley S et al (2017) Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 97(1):35–41. https://doi.org/10.1016/j.ijrobp.2016.10.004
doi: 10.1016/j.ijrobp.2016.10.004
pubmed: 27979454
van Nimwegen FA, Schaapveld M, Cutter DJ et al (2016) Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 34(3):235–243. https://doi.org/10.1200/JCO.2015.63.4444
doi: 10.1200/JCO.2015.63.4444
pubmed: 26573075
Ricardi U, Maraldo MV, Levis M, Parkih RR (2019) Proton therapy For lymphomas: current state of the art. Onco Targets Ther 12:8033–8046. https://doi.org/10.2147/OTT.S220730
doi: 10.2147/OTT.S220730
pubmed: 31632057
pmcid: 6781741
Iorio GC, Salvestrini V, Borghetti P et al (2021) The impact of modern radiotherapy on radiation-induced late sequelae: focus on early-stage mediastinal classical Hodgkin lymphoma a critical review by the young group of the italian association of radiotherapy and clinical oncology (AIRO). Crit Rev Oncol Hematol. 161:103326. https://doi.org/10.1016/j.critrevonc.2021.103326
doi: 10.1016/j.critrevonc.2021.103326
pubmed: 33862247
Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, Kelsay CR (2012) Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 84:762–767
doi: 10.1016/j.ijrobp.2011.12.067
pubmed: 22420972
Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B et al (2014) Modern radiation therapy for nodal non-Hodgkin lymphoma- target definition and dose guidelines from the international lymphoma oncology group. Int J Radiat Oncol Biol Phys 98:49–58
doi: 10.1016/j.ijrobp.2014.01.006
Specht L, Nissen NI (1988) Hodgkin’s disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavorable combination. Eur J Haematol 40:396–402
doi: 10.1111/j.1600-0609.1988.tb00847.x
pubmed: 3378595
Hull MC, Mendenhall NP, Colgan ME (2002) Subdiaphragmatic hodgkin’s disease: the University of Florida experiance. Int J Rad Oncol Biol Phys 52:161–166
doi: 10.1016/S0360-3016(01)01813-2
Akoum R, Brihi E, Saade M, Hanna T, Chahine G (2007) Salvage abdominal irradiation for refractory non-Hodgkin’s lymphoma. J Can Res Ther 3:143–149. https://doi.org/10.4103/0973-1482.37406
doi: 10.4103/0973-1482.37406
Brihi E, Akoum R, Saade M, Chanine G (2003) Abdominal irradiation after chemotherapy in non-Hodgkin’s lymphoma: review of 32 patients. Mol Immunol 39:1121–1128
doi: 10.1016/S0161-5890(03)00080-4
pubmed: 12835089
Glick JH, Kim K, Earle J et al (1995) An ECOG randomized phase III trial of CHOP vs CHOP plus radiotherapy for intermediate grade early stage NHL. Proc Am Soc Clin Oncol. 14:391
Miller TP, Dahlberg S, Cassady JR et al (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339:21–26
doi: 10.1056/NEJM199807023390104
pubmed: 9647875
Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H (2005) Groupe d’Etude des lymphomes de l’Adulte (GELA) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 352(12):1197–205. https://doi.org/10.1056/NEJMoa042040
doi: 10.1056/NEJMoa042040
pubmed: 15788496
Miller T, Leblanc M, Spier C et al (2001) CHOP alone compared with CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphomas: update of the Southwest Oncology Group (SWOG) Randomized trial. Blood. 98:a724
Aviles A, Delgado S, Nambo MJ, Alatriste S, Dias-Maqueo JC (1994) Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30:799–803
doi: 10.1016/0360-3016(94)90352-2
pubmed: 7525515
Ferreri AJ, Dell’Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, Villa E (2000) Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology 58:219–226. https://doi.org/10.1159/000012104
doi: 10.1159/000012104
pubmed: 10765124
Vargo JA, Gill BS, Balasubramani GK, Beriwal S (2015) Treatment selection and survival outcomes in early-stage diffuse-large B-cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol 33:3710–3717. https://doi.org/10.1200/JCO.2015.61.7654
doi: 10.1200/JCO.2015.61.7654
pubmed: 26261253
Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F et al (2010) Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28:4170–4176. https://doi.org/10.1200/JCO.2009.27.3441
doi: 10.1200/JCO.2009.27.3441
pubmed: 20713859
Follows GA, Ardeshna KM, Barrington SF et al (2014) Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 166:34–39. https://doi.org/10.1111/bjh.12878
doi: 10.1111/bjh.12878
pubmed: 24712411
Delclos L, Braun E J, Raul Herrera J (1963) Whole Abdominal irradiation by Cobalt-60Moving-Strip Technic. Radiology 81(4):632–641
doi: 10.1148/81.4.632
pubmed: 14078330
Surbone A, Longo DL, DeVita VT Jr, Ihde DC, Duffey PL et al (1988) Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 6:1832–1837. https://doi.org/10.1200/JCO.1988.6.12.1832
doi: 10.1200/JCO.1988.6.12.1832
pubmed: 3199167
Elsayad K, Eich HT (2015) Survival benefit by consolidating Radiotherapy in patients with diffuse large B-Cell lymphoma in early stages. Strahlenther Oncol 192:502–504. https://doi.org/10.1007/s00066-016-0992-x
doi: 10.1007/s00066-016-0992-x
Horning SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, Glick JH (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: EASTERN cooperative oncology group study 1484. J Clin Oncol 22(15):3032–3038. https://doi.org/10.1200/JCO.2004.06.088
doi: 10.1200/JCO.2004.06.088
pubmed: 15210738
Imber BS, Yahalom J (2020) Radiotherapy for non-Hodgkin lymphomas. Cancer J 26(3):217–230. https://doi.org/10.1097/PPO.0000000000000453
doi: 10.1097/PPO.0000000000000453
pubmed: 32496455
pmcid: 8436835
Levis M, Piva C, Filippi AR et al (2017) Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin’s lymphoma with incomplete response before autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk 17(1):14–22. https://doi.org/10.1016/j.clml.2016.09.008
doi: 10.1016/j.clml.2016.09.008
pubmed: 27727134
Wirth A, Corry J, Laidlaw C, Matthews J, Liew KH (1997) Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 39:599–607. https://doi.org/10.1016/s0360-3016(97)00352-0
doi: 10.1016/s0360-3016(97)00352-0
pubmed: 9336139
Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel MG et al (2018) The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 100(5):1100–1118. https://doi.org/10.1016/j.ijrobp.2018.01.011
doi: 10.1016/j.ijrobp.2018.01.011
pubmed: 29722655
Kahn S, Flowers C, Xu Z, Esiashvili N (2011) Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radat Oncol Biol Phys 81(1):175–180. https://doi.org/10.1016/j.ijrobp.2010.05.010
doi: 10.1016/j.ijrobp.2010.05.010
Campbell BA, Voss N, Woods R, Gascoyne RD, Morris R, Pickles T et al (2010) Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 116:3797–806. https://doi.org/10.1002/cncr.25117
doi: 10.1002/cncr.25117
pubmed: 20564082
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T et al (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: randomised phase III trial. Radiother Oncol. 100:86–92. https://doi.org/10.1016/j.radonc.2011.05.013
doi: 10.1016/j.radonc.2011.05.013
pubmed: 21664710
Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A et al (2019) Definitive radiotherapy for localized follicular lymphoma staged by
doi: 10.1182/blood-2018-04-843540
pubmed: 30446493
Pugh TJ, Ballonoff P, Newman F, Rabinovitch R (2010) Improved survival with patients with early stage low-grade follicular lymohoma treated with radiation: a surveilance, epidemiology and end results database analysis. Cancer. 116:3843–51. https://doi.org/10.1002/cncr.25149
doi: 10.1002/cncr.25149
pubmed: 20564102
Haas RL, Girinsky T (2003) HOVON 47/EORTC 20013: chlorambucil vs 2x2 Gy involved field radiotherapy in stage III/IV previously untreated follicular lymphoma patients. Ann Hematol 82:458–462
doi: 10.1007/s00277-003-0655-8
pubmed: 12756499
Hoskin P, Popova B, Schofield O, Brammer C, Robinson M, Brunt AM, Madhavan K, Illidge T, Gallop-Evans E, Syndikus I, Clifton-Hadley L, Kirkwood AA (2021) 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol 22(3):332–340. https://doi.org/10.1016/S1470-2045(20)30686-0 . (Epub 2021 Feb 1 PMID: 33539729)
doi: 10.1016/S1470-2045(20)30686-0
pubmed: 33539729
Russo AL, Chen YH, Martin NE, Vinjamoori A, Luthky SK, Freedman A et al (2013) Low-dose involved-field radiation in the treatment of non-Hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys. 86:121–7. https://doi.org/10.1016/j.ijrobp.2012.12.024
doi: 10.1016/j.ijrobp.2012.12.024
pubmed: 23414765
Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M et al (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21:2474–2480. https://doi.org/10.1200/JCO.2003.09.542
doi: 10.1200/JCO.2003.09.542
pubmed: 12829665
Valicenti RK, Wasserman TH, Monyak DJ, Kucik NA (1994) Non-hodgkin’s lymphoma: whole-abdomen irradiation as an adjuvant to chemotherapy. Radiology 192:571–576. https://doi.org/10.1148/radiology.192.2.8029434
doi: 10.1148/radiology.192.2.8029434
pubmed: 8029434
Goffinet R, Glatstein E, Fuks Z, Kaplan HS (1976) Abdominal irradiation in non-Hodgkin’s lymphoma. Cancer 37:2797–2806
doi: 10.1002/1097-0142(197606)37:6<2797::AID-CNCR2820370635>3.0.CO;2-H
pubmed: 949699
Coia LR, Hanks GE (1987) Complications from large field intermediate dose infradiaphragmatic radiation: an analysis of the patterns of care outcome studies for Hodgkin’s disease and seminoma. Int J Rad Oncol Biol Phys 15:29–35
doi: 10.1016/0360-3016(88)90343-4
Niemierko A, Goitein M (1993) Modeling of normal tissue response to radiation: the critical volume model. Int J Radiot Oncol Biol Phys 25:134–145
doi: 10.1016/0360-3016(93)90156-P
Galunić Bilić L, Šantek F (2018) Infradiaphragmal radiotherapy in patients with Lymphoma volume definition and side effects. Acta clinica Croatica. 57:554–560
pubmed: 31168189
pmcid: 6536292
Gallez-Marchal D, Fayolle M, Henry-Amar M, LeBourgeois JP, Rougier P, Cosset JM (1984) Radiation injuries of the gastrointestinal tract in Hodgkin’s disease: The role of exploratory laparotomy and fractionation. Radiother Oncol 2:93–99
doi: 10.1016/S0167-8140(84)80044-4
pubmed: 6505288
Langlios D, LeBourgeois JP, Leung S, Keuentz M (1985) Intestinal complications of wide field abdominal irradiation for lymphoma. Radiother Onkol 3:293–298
doi: 10.1016/S0167-8140(85)80041-4
Mahé MA, Bourdin S, Le Mevel A, Moreau P, Moreau A, Hamidou M, Gaillard F, Rapp MJ, Milpied N, Harousseau JL (1998) Long-term results of total abdominopelvic irradiation in non-Hodgkin’s lymphomas after failure of chemotherapy. Int J Radiat Oncol Biol Phys 41:117–121. https://doi.org/10.1016/s0360-3016(98)00034-0
doi: 10.1016/s0360-3016(98)00034-0
pubmed: 9588925
Kaplan HS (1980) Hodgkin’s Disease, 2nd edn. MA, Harvard University Press, Boston
Dawson LA, Kavanagh BD, Paulino AC et al (2010) Radiation-Associated Kidney Injury. Int J Radiat Oncol Biol Phys 76:108–115
doi: 10.1016/j.ijrobp.2009.02.089
Parikh RR, Grossbard ML, Harrison LB, Yahalom J (2016) Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma. Radiother Oncol. 118:52–59
doi: 10.1016/j.radonc.2015.10.022
pubmed: 26522061
Choi WH, Cho J (2016) Evolving clinical cancer radiotherapy: concerns regarding normal tissue protection and quality assurance. J Korean Med Sci 31(Suppl 1):S75–S87
doi: 10.3346/jkms.2016.31.S1.S75
pubmed: 26908993
pmcid: 4756347
Conway JL, Connors JM, Tyldesley S, Savage KJ, Campbell BA, Zheng YY, Hamm J, Pickles T (2017) Secondary breast cancer risk by Radiation volume in women with Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 97(1):35–41. https://doi.org/10.1016/j.ijrobp.2016.10.004
doi: 10.1016/j.ijrobp.2016.10.004
pubmed: 27979454
Oeffinger KC, Stratton KL, Hudson MM, Leisenring WM, Henderson TO et al (2021) Impact of risk-adapted therapy for pediatric Hodgkin Lymphoma on risk of long-term morbidity: a report from the childhood cancer Survivor study. J Clin Oncol 39(20):2266–2275. https://doi.org/10.1200/JCO.20.01186
doi: 10.1200/JCO.20.01186
pubmed: 33630659
pmcid: 8260906